Kinnate Biopharma gets grant for patent granted for cancer treatment using RAF inhibitor

17h ago, source: Pharmaceutical Technology

Discover how Kinnate Biopharma's patent revolutionizes cancer treatment with a RAF inhibitor, targeting specific genetic alterations for metastatic melanoma and non-small cell lung cancer.

KNTE Apr 2024 2.000 call(CONTRA

3d ago, source: Yahoo Finance

entered into a merger agreement to acquire Kinnate Biopharma Inc. (“Kinnate”; Nasdaq: KNTE) for (i) a base cash price per share of Kinnate common stock of $2.3352 per share Kinnate Biopharma ...

Latest News for KINNATE BIOPHARMA INC COM Stock (NASDAQ:KNTE)

1mon ago, source: Benzinga.com

Goldman Sachs Maintains Buy on Kinnate Biopharma, Lowers Price Target to $26 ...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

1mon ago, source: Morningstar

SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology ...

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

1mon ago, source: Business Insider

About Kinnate Biopharma Inc. Kinnate Biopharma Inc. is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of ...

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

9d ago, source: BioSpace

Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

17d ago, source: ADVFN

XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price ...

STRO Sutro Biopharma, Inc.

5d ago, source: Seeking Alpha

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated ...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

1mon ago, source: Morningstar

CASTRES, France and SAN FRANCISCO, March 1, 2024 /PRNewswire/ -- Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fabre ...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

1mon ago, source: PR Newswire

About Kinnate Biopharma Inc. For more information, visit Kinnate.com and follow the company on LinkedIn to learn about its most recent initiatives. This communication contains forward-looking ...

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

1mon ago, source: Yahoo Finance

CASTRES, France and SAN FRANCISCO, March 1, 2024 /PRNewswire/ -- Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate" or the "Company"), a clinical-stage precision oncology company, and Pierre Fabre ...